TAO WANG to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications TAO WANG has written about Antineoplastic Combined Chemotherapy Protocols.
Connection Strength
0.318
-
The prognosis of patients with primary osteosarcoma who have undergone unplanned therapy. Jpn J Clin Oncol. 2011 Nov; 41(11):1244-50.
Score: 0.207
-
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol. 2013 May 10; 31(14):1726-31.
Score: 0.057
-
Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma. Neuro Oncol. 2009 Jun; 11(3):292-300.
Score: 0.042
-
High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res. 2011 Apr 15; 17(8):2314-27.
Score: 0.012